AAIC 2026 | Targeted epigenome editing of APOE4 for Alzheimer’s disease treatment

Boris Kantor, PhD, Florida State University, Tallahassee, FL, discusses the innovative approach of gene therapy to treat complex diseases such as Alzheimer’s, highlighting the advantage of a one-shot treatment that targets the genetic root of the disease. Prof. Kantor explains his team’s main approach, which involves epigenome editing of genes involved in Alzheimer’s disease, specifically the ApoE isoform E4, using a CRISPR-Cas-based system that can target and repress APOE4 without affecting other isoforms. This interview took place at the 2026 Alzheimer’s Association International Conference (AAIC) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.